Digital health VC hits $7.4B in H1 2026 as AI agents, chronic care, and workforce tools capture mega-deal capital

Digital health venture funding hit $7.4 billion in the first half of 2026, with mega-deals of $100 million or more setting the tempo, according to Modern Healthcare reporting on Rock Health data. The concentration of capital in a handful of large rounds reflects a maturing market where investors are betting on platforms already operating at scale, not early-stage prototypes.

That dynamic was on full display in June. Four funding rounds alone totaled $335 million, spanning AI scheduling agents, chronic disease monitoring, home health operations, and healthcare workforce training, according to MedCity News. Each company deploying that capital has moved well past concept: they arrive with health system contracts, patient volumes, and, in some cases, valuation benchmarks that signal institutional-grade confidence.

Where the capital is landing: four categories, four rounds

Assort Health closed a $120 million Series C led by Menlo Ventures, with Lightspeed Venture Partners, Felicis, and First Round Capital among the participants, according to MedCity News. The company, now valued at $1.2 billion with $222 million raised in total, runs an AI agents platform built on more than 190 million patient interactions that handles scheduling, intake, referrals, document processing, medication refills, and payments. For health system operations leaders, the scale of the interaction data is the operative fact: training on that volume separates the platform from point solutions that are still learning basic intake workflows.

Cadence, a clinical AI company focused on chronic disease, secured $100 million in a Series C led by Spark Capital, with participation from Thrive Capital, General Catalyst, Coatue, and health system investors including Corewell Health Ventures, Memorial Hermann, and Duke Health, as reported by MedCity News. Cadence works with more than 20 health systems and monitors more than 100,000 patients, identifying risks and coordinating interventions. The health system co-investors are notable: they signal operational validation, not just financial interest.

Adaptive Innovations raised $60 million across a $50 million Series A and $10 million in seed funding, led by Felicis and Bain Capital Ventures, with Optum Ventures among the participants, per MedCity News. The company, launched in 2025, combines an AI operating system with in-home clinicians and has already completed more than 100,000 patient visits while partnering with more than 500 referring healthcare organizations. Home health has historically struggled to absorb complex technology; that visit volume in roughly one year of operation is a concrete counterpoint to that narrative.

Stepful brought in $55 million in a Series C led by Oak HC/FT, with participation from Foresite Capital, Intermountain Health, and Y Combinator, according to MedCity News. The company trains workers for roles including medical assistant, pharmacy technician, and dental assistant, then connects graduates to provider partners. Its announced expansion into registered nurse and imaging programs addresses the specific workforce gaps that hospital procurement teams have been trying to fill through contract labor, which carries higher unit costs than a trained-and-placed direct hire.

Staffing pressure and M&A integration are accelerating enterprise AI adoption

The funding activity does not exist in isolation. Hospitals are actively seeking AI vendors to fill revenue cycle management gaps created by staffing shortages and growing documentation complexity, according to Modern Healthcare. That pressure creates a direct procurement pathway for AI platforms that can demonstrate throughput improvements in billing and prior authorization, functions where labor costs have risen sharply and where errors carry direct revenue consequences.

On the M&A side, companies that made acquisitions in 2025 are now demonstrating results in 2026 through new health system partnerships and broader service lines, Modern Healthcare reported. That progress matters to procurement teams evaluating whether a vendor's post-acquisition integration risk is real: early evidence of product consolidation and partnership expansion after a deal reduces one of the most common objections in enterprise contract renewal conversations.

Tempus AI's announced $1.7 billion acquisition of cancer-technology firm Personalis, expected to close in late 2026 or early 2027, is the largest single deal in this cycle so far, per Modern Healthcare. It extends the logic of consolidation into genomics and oncology data, categories where scale of data assets directly determines the quality of AI outputs.

Early HTA: the evaluation framework that could separate durable investments from stranded ones

The funding surge raises a question that matters to every health system technology leader: which of these platforms will still be viable when a multi-year contract comes up for renewal? A study published in npj Health Systems by Nature offers a structural answer. It argues that applying health technology assessment at the R&D stage, rather than waiting for a regulatory filing, could help innovators identify the right disease targets, define credible value propositions, and make development choices that improve cost-effectiveness before they reach payer review.

Traditional HTA evaluates technologies late in their lifecycle, the Nature paper notes. By that point, if a product fails to secure reimbursement, neither the innovator nor the health system that piloted it has much recourse. Early HTA, applied during development, surfaces those reimbursement gaps while there is still time to redesign the product or redirect the target indication. For procurement teams, the practical implication is a new due-diligence question: has this vendor engaged with payer evidence requirements early, or is coverage an assumption rather than a plan?

The paper identifies a persistent misalignment between technology development driven by scientists and coverage policy shaped by governments, clinicians, and patients, a gap that rising health technology costs have made harder to ignore. Closing that gap through early assessment is not just an academic argument. It is the difference between a platform that generates return on a long-term health system contract and one that stalls at the reimbursement stage after the pilot is over.

What this means for your team

• Validate reimbursement readiness: ask AI vendors whether they have conducted early health technology assessment or engaged payers on coverage evidence before reaching contract discussions, not after.
• Scrutinize health system co-investors: when an investor syndicate includes operating health systems such as Corewell, Memorial Hermann, or Duke, treat that as a signal of clinical validation, then ask which specific use cases those systems have deployed at scale.
• Pressure-test workforce AI on placement rates: for platforms like Stepful that combine training with employer placement, the operational metric is graduate-to-hire conversion within your specific role categories, not overall certification volume.
• Apply M&A integration timelines to renewal decisions: if a vendor made a significant acquisition in 2025, ask for concrete evidence of product integration and joint customer results before a 2026 or 2027 contract extension.